Frio Oral Rinse
PreclinicalSmall molecule
Frio Oral Rinse is one of 5 small molecule programs targeting Oral Candidiasis. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Oral Candidiasis
#DrugCompanyPhaseTrials
1Lotrimin
BayerApproved
Mycostatin
GGood Molecules, LLC
Approved
Inomax
MMallinckrodt
Approved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Frio Oral Rinse
BBiomedical Development Corporation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Frio Oral Rinse. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details